Physician profile
Alan D Abrams
NPI 1053373621
$3,628.36
in general payments reported to CMS, 2019-2025
21 companies · $562 in 2025
The $562 reported for 2025 was more than what 82% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $816 · 2022: $788 · 2023: $879 · 2024: $584 · 2025: $562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,025.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,025.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $448.20 | 2021-2025 | Epclusa |
| Sk Life Science, INC. | $370.32 | 2022-2024 | Xcopri |
| Novo Nordisk INC | $315.63 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $255.49 | 2021-2023 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $244.77 | 2023-2024 | |
| Actelion Pharmaceuticals US, INC. | $233.21 | 2025 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $231.77 | 2021-2024 | Jardiance |
| Lundbeck LLC | $211.69 | 2022-2023 | Vyepti |
| Pharming Healthcare, INC. | $124.92 | 2024 | Joenja |
| Smith+Nephew, INC. | $123.81 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $123.54 | 2023 | Rexulti |
| Viatris Specialty LLC | $123.44 | 2025 | Yupelri |
| Amgen INC. | $121.44 | 2021 | |
| Corium, LLC | $120.15 | 2023 | Azstarys |
| Pfizer INC. | $99.71 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $98.83 | 2021 | |
| Abbvie INC. | $96.44 | 2021 | |
| Dynavax Technologies Corporation | $84.59 | 2025 | Heplisav-B |
| Boston Scientific Corporation | $83.73 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $66.75 | 2023 | |
| Alexion Pharmaceuticals, INC. | $49.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Abrams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.